No description
-
2009 (v1)PublicationUploaded on: March 27, 2023
-
2017 (v1)Publication
Inflammation plays an essential role in the development and complications of atherosclerosis plaques, including acute coronary syndromes (ACS). Indeed, previous reports have shown that within the coronary circulation of ACS patients, several soluble mediators are released. Moreover, it has been demonstrated that endothelial dysfunction might...
Uploaded on: March 27, 2023 -
2015 (v1)Publication
Purpose: In colorectal cancer, the activation of the intracellular RAS–RAF and PIK3CA–AKT pathways has been implicated in the resistance to anti-EGFR mAbs. We have investigated the role of regorafenib, an oral multikinase inhibitor, in combination with cetuximab, an anti-EGFR mAb, to overcome anti-EGFR resistance. Experimental Design: We have...
Uploaded on: April 14, 2023 -
2006 (v1)Publication
Background—Recent studies indicate that T-cell activation may play an important role in the pathophysiology of acute coronary syndromes (ACS). However, although those studies detected T-cell expansion in peripheral blood cells, demonstration of specific T-cell expansion within the plaque of patients with ACS is lacking. The present study...
Uploaded on: April 14, 2023 -
2013 (v1)Publication
The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of different transducer molecules in these pathways have been developed as molecular targeted anti-cancer therapies. The in vitro and in vivo anti-tumor activity of pimasertib, a selective MEK 1/2...
Uploaded on: April 14, 2023 -
2008 (v1)Publication
We demonstrate that CD161 is a highly up-regulated gene in human interleukin (IL) 17 T helper cell (Th17) clones and that all IL-17 – producing cells are contained in the CD161 + fraction of CD4 + T cells present in the circulation or in infl amed tissues, although they are not CD1-restricted natural killer T cells. More importantly, we show...
Uploaded on: March 27, 2023